### Contents

**Monthly Volume 13 Number 5 May 24, 2022**

#### MINIREVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

#### ORIGINAL ARTICLE

**Basic Study**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>323</td>
<td>Tumor specifically internalizing peptide ‘HN-1’: Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis</td>
<td>Hong FU, Castro M, Linse K</td>
</tr>
</tbody>
</table>

**Retrospective Study**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>352</td>
<td>Survival characteristics of fibrolamellar hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results database study</td>
<td>Sempokuya T, Forlema A, Azawi M, Silangcruz K, Khoury N, Ma J, Wong LL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>366</td>
<td>Modified binding pancreaticogastrostomy vs modified Blumgart pancreaticojejunostomy after laparoscopic pancreaticoduodenectomy for pancreatic or periampullary tumors</td>
<td>Choudhury SR, Kalayarasan R, Gnanasekaran S, Pottakkat B</td>
</tr>
</tbody>
</table>

**Observational Study**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

#### SYSTEMATIC REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>388</td>
<td>Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials</td>
<td>Poulose JV, Kainickal CT</td>
</tr>
</tbody>
</table>

#### LETTER TO THE EDITOR

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>412</td>
<td>Commentary: Evaluating potential glioma serum biomarkers, with future applications</td>
<td>Goutnik M, Lucke-Wold B</td>
</tr>
</tbody>
</table>
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world

ABOUT COVER
Editorial Board Member of World Journal of Clinical Oncology, Fabrício Freire de Melo, PhD, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Candeias, Vitória da Conquista, Bahia 45029-094, Brazil. fabricio.freire@ufba.br

AIMS AND SCOPE
The primary aim of World Journal of Clinical Oncology (WJCO, World J Clin Oncol) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING
The WJCO is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2021 edition of Journal Citation Reports® cites the 2020 Journal Citation Indicator (JCI) for WJCO as 0.48.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Wen-Wen Qi; Production Department Director: Xu Guo; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL
World Journal of Clinical Oncology

ISSN
ISSN 2218-4333 (online)

LAUNCH DATE
November 10, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2218-4333/editorialboard.htm

PUBLICATION DATE
May 24, 2022

COPYRIGHT
© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Basic Study

Tumor specifically internalizing peptide ‘HN-1’: Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis

Frank-Un Hong, Miguel Castro, Klaus Linse

Specialty type: Oncology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind

BACKGROUND
Less than 0.5% of intravenously injected drugs reach tumors, contributing to side effects. To limit damage to healthy cells, various delivery vectors have been formulated; yet, previously developed vectors suffer from poor penetration into solid tumors. This issue was resolved by the discovery of HN-1 peptide isolated via biopanning a phage-display library. HN-1 targets human head and neck squamous cell carcinoma (HNSCC) (breast, thyroid; potentially lung, cervix, uterine, colon cancer), translocates across the cell membrane, and efficiently infiltrates solid tumors. HN-1 peptide has been conjugated to various anticancer drugs and imaging agents though the identity of its receptor remained enigmatic.

AIM
To decipher the clues that pointed to retinoblastoma (Rb)-regulated discoidin-domain receptor 1 as the putative receptor for HN-1 is described.

METHODS
HN-1 peptide was synthesized and purified using reverse-phase high-performance liquid chromatography and gel electrophoresis. The predicted mass was confirmed by mass spectroscopy. To image the 3-dimensional structure of HN-1 peptide, PyMOL was used. Molecular modeling was also performed with PEP-FOLD3 software via RPBS bioinformatics web portal (INSERM, France). The immunohistochemistry results of discoidin domain receptor 1 (DDR1) protein were obtained from the publicly accessible database in the Human Protein Atlas portal, which contained the images of immunohistochemically labeled human cancers and the corresponding normal tissues.

RESULTS
The clues that led to DDR1 involved in metastasis as the putative receptor...
mediating HN-1 endocytosis are the following: (1) HN-1 is internalized in phosphate-buffered saline and its uptake is competitively inhibited; (2) HN-1 (TSPLNIHNGQKL) exhibits similarity with a stretch of amino acids in alpha5 beta3 integrin (KLLITIHDRKEF). Aside from two identical residues (Ile-His) in the middle, the overall distribution of polar and nonpolar residues throughout the sequences is nearly identical. As HN-1 sequence lacks the Arg-Gly-Asp motif recognized by integrins, HN-1 may interact with an ‘integrin-like’ molecule. The tertiary structure of both peptides showed similarity at the 3-dimensional level; (3) HN-1 is internalized by attached cells but not by suspended cells. As culture plates are typically coated with collagen, collagen-binding receptor (expressed by adherent but not suspended cells) may represent the receptor for HN-1; (4) DDR1 is highly expressed in head and neck cancer (or breast cancer) targeted by HN-1; (5) Upon activation by collagen, DDR1 becomes internalized and compartmentalized in endosomes consistent with the determination of ‘energy-dependent clathrin-mediated endocytosis’ as the HN-1 entry route and the identification of HN-1 entrapped vesicles as endosomes; and (6) DDR1 is essential for the development of mammary glands consistent with the common embryonic lineage rationale used to identify breast cancer as an additional target of HN-1. In summary, collagen-activated tyrosine kinase receptor DDR1 overexpressed in HNSCC assumes a critical role in metastasis. Further studies are warranted to assess HN-1 peptide’s interaction with DDR1 and the therapeutic potential of treating metastatic cancer. Additionally, advances in delivery (conformation, endocytic mechanism, repertoire of targeted cancers of HN-1 peptide), tracking (HN-1 conjugated imaging agents), and activity (HN-1 conjugated therapeutic agents) are described.

CONCLUSION
The discovery of DDR1 as HN-1 peptide’s putative receptor represents a significant advance as it enables identification of metastatic cancers or clinical application of previously developed therapeutics to block metastasis.

Key Words: HN-1 peptide; Solid tumor; Targeted drug delivery; Discoidin domain receptor 1; Tyrosine kinase; Metastasis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The side effects associated with current drugs are exacerbated by the accumulation of administered drugs in non-tumor tissues. To guide, various tumor-homing vectors have been developed though their delivery efficacy is limited by poor penetration into solid tumors. To resolve, the ‘tumor specifically internalizing peptide’ HN-1 was isolated via biopanning a phage-display library. HN-1 peptide targets human head and neck squamous cell carcinoma (breast, thyroid, potentially cervical, lung, uterine, colon cancer), translocates across the cell membrane and effectively penetrates solid tumors. Here, deciphering of the clues that pointed to discoidin domain receptor 1 as the putative receptor for HN-1 is described.

Citation: Hong FU, Castro M, Linse K. Tumor specifically internalizing peptide ‘HN-1’: Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis. World J Clin Oncol 2022; 13(5): 323-338
URL: https://www.wjgnet.com/2218-4333/full/v13/i5/323.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i5.323

INTRODUCTION
The genetic analysis of head and neck cancer has uncovered novel therapeutic targets. Head and neck cancer represents ~5% of all cancers diagnosed in the United States and the affected regions include the oral cavity, paranasal sinuses, pharynx, nasal cavity, larynx, thyroid gland, parathyroid gland, salivary gland, skin or cervical lymph nodes. Aesthetic loss or functional impairment (ex. difficulties with swallowing, speech, chewing) frequently accompany the disorder. Squamous cells constitute the mucosal membranes lining the lips, mouth, throat, breathing tubes, nose, eyelids, etc. and head and neck squamous cell carcinoma (HNSCC) (the second most common type of skin cancer) affects more men than women. Its mortality rate (~50%) has not changed significantly over the past several decades although early diagnosis may increase survival. Most HNSCC-associated deaths are caused by loco-regional recurrence or distant metastasis[1].
Epithelial carcinogenesis leading to head and neck cancer involves progression through multiple stages (from normal to hyperplasia to dysplasia to carcinoma to invasive carcinoma) accompanied by distinct genetic changes. Among the alterations are the loss of heterozygosity at chromosomal region 9p21 or 3p12-14 (squamous dysplasia, carcinoma in situ, invasive carcinoma), loss of heterozygosity at 9p21 or 3p14 (oral leukoplakia), and translocation between chromosomes 11 and 19 (mucoepidermoid carcinoma of the minor salivary gland). Microsatellite instability is observed in a subset of dysplastic, invasive, and aggressive lesions while aneuploidy is a frequent occurrence amongst HNSCC tumors[2].

The inactivation of retinoblastoma (Rb) function represents a critical step in HNSCC development. Briefly, following the identification of the prototypic tumor suppressor Rb gene, its role in mammalian DNA damage checkpoint (in G1 or S phase) was elucidated[3]. Rb’s ability to arrest at G1 is negatively regulated by distinct cyclin-dependent kinases (Cdks) through phosphorylation by cyclin D-Cdk4/6 at early G1 phase and cyclin E-Cdk2 late G1 phase[4,5]. Cdks are, in turn, negatively regulated by p14[ARF], p16[INK4A], or other factors including p21[CDKN1], which is transactivated by p53. The above ‘Rb pathway’ is dysregulated in nearly all human cancers and is also targeted by oncogenic viruses (ex. papillomavirus, adenovirus) to transform human cells. In HNSCC, the loss of p16[INK4A] is characteristic of hyperplasia and the loss of 3p21 and 17p13 (inactivates p53) is observed during progression to dysplasia. The amplification of the CCND1 gene (encodes cyclin D) and the loss of 11q13, 14q32, or 13q21 is associated with carcinoma. The loss of 6p, 4q27, 8 or 10q23 as well as the inactivation of phosphatase and tensin homolog (PTEN) has been documented in invasive carcinoma[6]. In a significant fraction of HNSCC patients with poor prognosis, human papillomavirus DNA is found in tumors, whose gene product E7 inactivates Rb while E6 inactivates p53. Additionally, FAT1, NOTCH1, KMT2D, TGFBR2, PIK3CA, and HER-2/neu are frequently upregulated in a subset of HNSCC[2].

The above advances have led to the development of targeted therapies, i.e., Cdk4/6 inhibitor, epidermal growth factor receptor inhibitor, etc. However, even with targeted drugs, the problem of side effects persists. Furthermore, less than 0.5% of systemically administered drugs reach tumors, requiring a higher dose for treatment which exacerbates side effects[7]. To resolve, tumor-homing vectors are increasingly sought for targeted delivery of existing drugs. In the case of HNSCC, ‘sac’-like structures contain tumor cells enclosed within the basement membrane. The parenchyma is comprised of tumor cells with intercellular spaces. A solid tumor may contain multiple such ‘sacs’ interspersed within the stroma. Stroma is a complex structure comprised of cytokeratin and normal cells, ex. fibroblasts, endothelial cells, immune cells. As such, an ideal delivery vector should be capable of penetrating these barriers to reach tumor cells located at the interior of the sac-like structures.

For targeted delivery, antibodies recognizing tumor-specific antigens such as CD20 (B-cell lymphoma), HER-2 (breast cancer), CD33 (acute myeloid leukemia), epidermal growth factor receptor have been developed. Anticancer agents conjugated to these antibodies include radioactive isotopes (non-Hodgkin’s lymphoma) and chemotherapeutics, ex. doxorubicin, maytansine, and calicheamicin (acute myelogenous leukemia). Alternatively, larger molecules such as polyethylene glycol have been used as they can escape through leaky tumor vasculature to deposit on a tumor. The leakage occurs primarily at venules and small veins that are lined by a continuous endothelium. Their exiting route consists of a system of vesiculo-vacuolar organelles, cell junction, or endothelial fenestrae. Previously, polyethylene glycol has been conjugated to taxol or tumor-specific antibodies. Also, liposomes have been utilized as they can accumulate at the tumor due to enhanced permeability and retention. Liposomes deliver drugs via fusion, destabilization of the membrane or endocytosis. Liposomes conjugated to polyethylene glycol exhibit greater stability due to lesser removal by the reticuloendothelial system[8]. Pegylated liposomes containing doxorubicin or cisplatin or liposomes coupled to tumor-targeting molecules have been developed.

However, the above delivery vectors face several limitations. For antibody vectors, its preparation or purification is complex due to the relative ease with which antibodies can denature. Other potential issues are immunogenicity (requires humanization) and the lack of internalization by the cancer cells. Poor penetration of solid tumors by antibodies further limits their use and may contribute to a higher level of drugs in circulation contributing to toxicity, ex. Herceptin antibody penetrates mere 38 micrometers after exiting blood vessels[9]. For these reasons, its use has been limited to lymphocytic cancers. For minute micrometastasized tumors that rely on nutrients obtained from adjacent blood vessels via diffusion, nanoparticles such as polyethylene glycol or liposome-based vectors that escape through leaky tumor vasculature may find little utility. The use of liposomes is delimited by the inefficient release of the enclosed drugs[10]. Overall, inefficient penetration of solid tumors has been a major issue with larger nanoparticles. As the interior of solid tumors may harbor hypoxic regions that give rise to refractory metastatic cancer cells to which patients ultimately succumb, the need to develop delivery vectors with greater infiltrating potential remains a priority[11].

The above issues have been largely resolved through the discovery of the prototypic ‘tumor specifically internalizing peptide’ HN-1, which was reported in Cancer Research in 2000[12]. HN-1 peptide is unique as it provided multiple advantages including tumor-selectivity for HNSCC, the capacity to translocate across the cell membrane, and the ability to penetrate solid tumors to reach cancer cells located within the sac-like structures. Since its discovery, HN-1 has been conjugated to various agents for both cancer therapy (taxol, doxorubicin, protein kinase C inhibiting peptide, ribonucleotide reductase inhibiting siRNA, diphtheria toxin, polyethylene glycol linked to doxorubicin,
graphene oxide nanoparticle-containing doxorubicin) and imaging (gamma-ray emitting isotopes for radiotherapy, near-infrared fluorescent dyes for surgical navigation) (see below). Recently, the target of HN-1 has been extended to breast cancer, thyroid cancer, and potentially cervical, lung, uterine, or colon cancer. Here, we describe the deciphering of clues that helped to unravel a 20 year-old enigma regarding the identity of the receptor mediating HN-1 endocytosis. Discoidin domain receptor 1 (DDR1) is a collagen tyrosine kinase overexpressed in head and neck cancer (also breast cancer), and the transcription of DDR1 gene is regulated by the RB-interacting protein E2F.[13] DDR1 differs from conventional tyrosine kinases as it is activated by collagen, and plays a critical role in metastasis by facilitating invasion or migration, promoting epithelial-to-mesenchymal transition, reactivating previously disseminated metastasis-initiating cancer cells, etc. As such, it has become a novel therapeutic target of high importance for the pharmacological management of metastatic cancers (see below).

**MATERIALS AND METHODS**

**Peptide**

HN-1 peptide was synthesized and purified using reverse-phase high-performance liquid chromatography to attain ~95% purity. For in vivo application, it was further purified using gel electrophoresis. The predicted mass was confirmed by mass spectroscopy.

**Molecular modeling**

PyMOL (Python-enhanced molecular graphics) was used to image the 3-dimensional structure of the HN-1 peptide. Additional molecular modeling was performed using PEP-FOLD3 software via RPBS (Ressource Parisienne en Bioinformatique Structurale) bioinformatics web portal (INSERM, France) (https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/)[14,15].

**Immunohistochemistry**

The immunohistochemistry images of DDR1 protein in a panel of human head and neck cancer specimens vs normal human oral mucosa were obtained from the publicly accessible database in the Human Protein Atlas portal (http://www.proteinatlas.org/). It contained the images of immunohistochemically labeled human cancers and the corresponding normal tissues.

**RESULTS**

**Structure of HN-1 peptide**

F. Hong (a.k.a. Frank Un, Frank D. Hong)’s contributions to the RB gene field was previously described [16]. Briefly, for cancer biology and genetics, his works include the identification of the human RB gene and its sequence containing cyclin-dependent kinase recognition motifs[3], determination of RB genome structure including the promoter[17] and its mutant in prostate cancer[18], the discovery of the DNA binding property of Rb protein indicative of its function as a transcription factor[19], uncovering of RB-to-RB self-interaction to form higher-ordered structures implicating its role in epigenetics, DNA replication, histone modification, heterochromatin, DNA condensation, etc[20-23]. For cancer therapy, his works concerned elucidating the cytotoxic mechanism of anticancer drugs to solve the side effects or drug resistance problem. He discovered tumor-specific lytic path ‘hyperploid progression mediated death’ targeting G1 DNA damage checkpoint-defective RB or p53 mutants induced by antimicrotubule drugs (ex. Taxol)[24], RB’s role as the mediator of DNA crosslinking drug cytotoxicity (ex. cisplatin) in RB’s role as the mediator of DNA crosslinking drug cytotoxicity (ex. cisplatin) in G1 checkpoint retaining human cancers[25], and the reversal of drug resistance to antimetabolite drugs (ex. hydroxyurea) via attenuating the RB-associating protein ICBP90 (UHRF1)[26].

Following the identification of the human RB gene, W. Lee (University of California at San Diego, La Jolla, United States) collaborated with T. Friedmann (University of California at San Diego, La Jolla, United States) to develop a recombinant retrovirus expressing human RB or p53 gene during 1988-1993. The retrovirally expressed RB or p53 suppressed the formation of tumors derived from human retinoblastoma, breast, or prostate cancer cells in murine xenograft models[27-29]. These works led to gene therapy clinical trials testing the efficacy of p53 expressing retrovirus or adenovirus in non-small cell lung cancer patients by J. Roth (University of Texas M. D. Anderson Cancer Center, Houston, United States) in 1996 and HNSCC patients by G. Clayman (University of Texas M. D. Anderson Cancer Center, Houston, United States) in 1998[30,31]. The clinical trial was conducted in collaboration with W. K. Hong (University of Texas M. D. Anderson Cancer Center, Houston, United States), who pioneered the chemoprevention of cancer[32]. Despite the therapeutic gains made in gene transduction, gene expression, and clinical response, further improvement was necessary regarding tumor specificity, solid tumor penetration, and in vivo stability.
The side effects occurred as the RB or p53 expressing recombinant virus indiscriminately infects both cancer and normal cells. To provide tumor specificity, F. Hong sought to identify a human HNSCC-specific peptide to be displayed on the surface of viral vectors. Earlier In 1984-1985, he used M13 single-stranded bacteriophage to perform site-directed mutagenesis at the Salk Institute (Molecular Biology & Virology Laboratory). Later, in 1993-1995, he worked with normal human fibroblasts while studying the mechanism of aging at the Salk Institute (Neurobiology Laboratory). During 1998-2000, F. Hong screened M13 bacteriophage-displayed random peptide libraries (2.5 × 10^12 random peptides) using live cancer cells at the University of Texas M. D. Anderson Cancer Center[12]. Filamentous phages displaying peptides fused to coat proteins were designed by G. Smith (Nobel prize, 2018). The biopanning involved 5 successive rounds of selection using human HNSCC cells, followed by 3 cycles of subtraction using normal human fibroblasts in the presence of serum to ensure stability in vivo. It led to the discovery of HN-1 peptide (TSPLNIHNGQKL; ~1.2 kDa) that meets multiple criteria for targeted drug delivery into solid tumors: (1) Translocates drugs across the cell membrane into the cytosol; (2) Tumor specifically internalized; and (3) Capable of penetrating solid tumors. Further, HN-1 peptide is nontoxic, nonimmunogenic, stable in vivo, transports payload efficiently within 48 h, and does not trigger biological responses.

Recent researches increasingly indicate the dynamic nature of protein structures, i.e., ‘intrinsically disordered protein’[33]. Despite the conformational flexibility, they can adopt a fixed or rigid structure upon recognizing the interacting target. Such properties have been harnessed by peptides, which provide further advantages over antibodies or small molecules for pharmaceutical treatment, resulting in the approval of > 60 peptide drugs worldwide in the last two decades. In the case of HN-1, computational modeling predicted several structural conformations. A 3-dimensional model depicting HN-1 peptide in a beta-sheet configuration is shown (Figure 1A). Alternate conformations of HN-1 peptide predicted by the PEP-FOLD modeling program are also shown (Figure 1B). Finally, a structural model consisting of a gamma-turn is shown (Figure 1C).

**DDR1 may mediate HN-1 endocytosis**

The treatment issue of recurrent metastatic cancer refractory to current drugs remains unresolved for HNSCC as well as breast cancer. The dysregulation of the extracellular matrix dynamics is thought to play a significant role in metastasis. The extracellular matrix is comprised of glycoproteins, proteoglycans, and other proteins that function in biomechanics, cell motility, growth factor reservoir, cell-to-cell communication, etc. An early event in tumor development involves neovascularization (for nutrient, oxygen, etc., to support the growth of tumor cells), which requires the outgrowth of blood vessels (endothelial branches) mediated by tip cells and stalk cells that depend on the extracellular matrix. The extracellular matrix also attracts immune cells and activates them to release cytokines and proteases (causes tumor-associated inflammation) while suppressing the activation of macrophages that lyse cancer cells. The dysregulated extracellular matrix exhibits altered activities of remodeling enzymes (e.g., collagenase or metalloprotease secreted by stroma), excess deposition of the matrix components (e.g., collagen types I, IV or VII) for tumor cells, cancer-associated fibroblasts or tumor-associated macrophages in colorectal cancer; heparan sulfate proteoglycan), stiffness through the crosslinking by lysyl oxidase, etc. Distinct collagen types found in the microenvironment of various cancers have been compiled, e.g., type I (head and neck squamous cell carcinoma, non-small cell lung cancer, breast cancer), type III (breast cancer), type IV (oral squamous cell cancer, colorectal cancer)[34]. Other changes include the altered orientation (linearization) of collagen fibers, which facilitates tumor cell migration (for invasion into adjacent tissues following the breakdown of basement membrane by matrix metalloproteinase)[35]. Further, the extracellular matrix is involved in the development of lymphatic vessels that serve as a conduit (in addition to the leaky tumor vasculature) for metastasis.

Discoidin domain receptors DDR1 and DDR2 are cell membrane-associated receptors with tyrosine kinase activity, whose extracellular domain resembles discoidin of *Dictyostelium discoideum*. DDR1 is activated by most collagen types including I and IV (abundant in the basement membrane) whereas DDR2 is activated by fibrillar collagen types I, III, and X but not II or IV[36]. Discoidin domain receptors regulate cell adhesion, growth, polarity, and migration through sensing extracellular matrix and interacting with TGF-beta, Notch, or adhesive receptors for signaling. The stromal-epithelial interaction mediated by DDR1 is essential for the normal development of mammary glands in mice[37]. DDR1 promotes cancer progression by facilitating the migration of squamous cell carcinoma cells[38], bone metastasis by lung cancer[39], lung metastasis by breast cancer[40], stroma-induced peritoneal metastasis of gastric cancer[41], and tissue invasion by metastatic colorectal cancer cells[42]. Mechanistically, activation of DDR1 by collagen induces matrix metalloproteinase to degrade extracellular matrix[43]. DDR1 overexpression in oral squamous carcinoma is involved in angiolympathic invasion[44]. DDR1 is involved in invasome formation via collagen-mediated activation of Rho-GTPase Cdc42[45]. DDR1 facilitates the invasion of a collective group of tumor cells by modulating actomyosin contractility at the cell-cell contacts[38]. Collagen type IV was shown to activate DDR1 to induce migration of breast cancer cells[46]. The epithelial-to-mesenchymal transition represents a critical step for metastasis and is triggered by extracellular matrix molecules or growth factors. The triggering by collagen type I is mediated by DDR1, whose signaling is transduced by proline-rich tyrosine kinase 2 to upregulate N-cadherin[47]. The DDR1 expression positively correlates with epithelial-to-mesenchymal transition in...
Figure 1 Three-dimensional structure of HN-1 peptide. A: A 3D model of HN-1 peptide generated using PyMol molecular graphics system, version 1.2r3pre, Schrödinger, LLC. All graphics depict an identical configuration with the bottom two panels in the opposite orientation; B: An ensemble of de novo conformations generated by PEP-FOLD (INSERM, France) in RPBS bioinformatics web portal: https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/; C: A 3-dimensional profile of the lowest energy structure obtained for HN-1 peptide was viewed using Raswin computer modeling software. All structures were generated using TSPLNIHNGQKL as the raw input peptide sequence. N1: The N-terminal residue.

Figure 1 Three-dimensional structure of HN-1 peptide. A: A 3D model of HN-1 peptide generated using PyMol molecular graphics system, version 1.2r3pre, Schrödinger, LLC. All graphics depict an identical configuration with the bottom two panels in the opposite orientation; B: An ensemble of de novo conformations generated by PEP-FOLD (INSERM, France) in RPBS bioinformatics web portal: https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/; C: A 3-dimensional profile of the lowest energy structure obtained for HN-1 peptide was viewed using Raswin computer modeling software. All structures were generated using TSPLNIHNGQKL as the raw input peptide sequence. N1: The N-terminal residue.
Figure 2 Discoidin domain receptor 1 may mediate HN-1 endocytosis. Discoidin domain receptor 1 (DDR1) protein is upregulated in human head and neck squamous cell carcinoma. Immunohistochemical analysis of DDR1 was conducted by comparing tumor vs normal tissues in Human Protein Atlas database (http://www.proteinatlas.org/). The results showed positive cytoplasmic and membranous staining. Bar: 25 micrometers; DDR1: Discoidin domain receptor 1.
Figure 3 HN-1 peptide exhibits similarity to integrin peptide. A: The similarities between the HN-1 sequence (TSPLNIHNGQKL) and a stretch of amino acids in alpha5 beta3 integrin (KLLITIHDRKEF) are highlighted. As HN-1 peptide lacks the recognition motif (RGD) of integrin, HN-1 may interact with an “integrin-like” molecule. HN-1 is internalized by attached cells but not by suspended cells. As tissue culture plates are typically coated with collagen, collagen-binding DDR1 receptor (expressed by adherent but not suspended cells) may represent the receptor for HN-1 consistent with that DDR1 is overexpressed in human head and neck cancer (also breast cancer) targeted by HN-1. avb3: alpha5 beta3; B: Comparison of 3D models generated by PEP-FOLD (INSERM, France) in RPBS bioinformatics web portal: https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/ TSPLNIHNGQKL: HN-1 peptide (top panels); KLLITIHDRKEF, membrane proximal sequence of beta subunit’s cytoplasmic tail in alpha5 beta3 integrin (bottom panels); TSPLNIHNGQKL: Thr-Ser-Pro-Leu-Asn-Ile-His-Asn-Gly-Gln-Lys-Leu; KLLITIHDRKEF: Lys-Leu-Leu-Ile-Thr-Ile-His-Asp-Asp-Lys-Glu-Phe.

derived tumors in a mouse xenograft model[12,57,59,62,65]. In contrast, HN-1 was poorly uptaken by their normal counterpart (human oral keratinocytes HOK16B, NOE human normal oral epithelial cells, NHDF normal human dermal fibroblasts)[12,58,59].

Recent works have uncovered additional cancer types targeted by HN-1 peptide (Figure 4A). HN-1 uptake was also observed with human large cell lung carcinoma H460a cells[64]. Also, the HN-1 derived peptide HN17 (contains rearranged HN-1 sequence) was internalized by MZ-CRC 1 and TT human thyroid cancer cells[66]. HN-1 was also shown to target breast cancer irrespective of their ‘triple status’. HN-1 or HN-1TYR (HN-1 with two extra tyrosine residues added N-terminally) was internalized by MDA-MB231, SKBR3, MDA-MB-468, ZR-75-1, or MCF-7 breast cancer cells while MCF10A nontumorigenic mammary epithelial cells exhibited little HN-1 uptake[58,59]. Additionally, HN-1 was internalized by MDA-MB-435, MDA-MB-231, and MTLn3 breast cancer cells[64]. Further, HN-1 was internalized by KB cells[58] (originally human oral epidermoid carcinoma cells but subsequently found to contain HeLa human cervical adenocarcinoma cells)[67], raising the prospect that HN-1 may target
Figure 4 The repertoire of targeted cancers and therapeutic application of HN-1 peptide. A: HN-1 uptake profile. The internalization of HN-1 peptide by various human cancer cells vs the corresponding normal human cells was compared. HN-1 uptake: red arrow (internalized), blue arrow (undetectable); B: Previously developed HN-1 based conjugates for therapy or diagnosis. Note: whether HN-1 peptide (consisting of a permutated version of HN-1 sequence) enters cells via the same route as HN-1 peptide or through a distinct route is not known. HOK: Human oral keratinocyte; NOE: Normal oral epithelial; NHDF: Normal human dermal fibroblasts; Cu: Copper; Tc: Technetium; PKCe: Protein kinase C epsilon; siRNA: Small interfering RNA; PEG: Polyethylene glycol.

For uterine cancer, HN-1 uptake by MES-SA/Dx5, a multi-drug resistant cell-line derived from the human uterine sarcoma cell line MES-SA, was documented[64]. For gastrointestinal cancer, HN-1 uptake was observed with human colorectal carcinoma LS513 and LS1034 cells[64].

HN-1 peptide translocates across the cell membrane to facilitate drug delivery. Upon entry, HN-1 is localized in punctate particles, which were subsequently identified as endosomes[57,60]. Multiple reports suggest that HN-1 is internalized via the ‘receptor-mediated endocytosis’: (1) The internalization of HN-1 is ‘specific’ (based on competition assay); (2) HN-1 can be uptaken in a serum-free medium (i.e., its receptor is cell-associated); (3) HN-1 is compartmentalized in endosomes after entry; and (4) Fusing the translocation domain of diphtheria toxin allows HN-1 to escape from the endosome into the cytosol. Using inhibitors of various entry routes (receptor-dependent endocytosis, pinocytosis, simple transmembrane diffusion, caveolae-mediated pathway), HN-1 uptake was shown to be mediated by ‘energy-dependent clathrin-mediated endocytosis’[57].

HN-1 efficiently penetrates tumor mass, which is significant as > 90% of human cancers are comprised of solid tumors. The intravenously injected HN-1 was localized at the interior of solid tumors derived from MDA177Tu or MDA167Tu human HNSCC cells in a mouse xenograft model[12]. An independent report showed that the intravenously injected HN1 penetrates solid tumors derived from UMSCC1 human HNSCC cells in vivo[59]. Using radiolabeled HN-5 peptide, a derivative of HN-1, its penetration into solid tumors formed by SCC4 human HNSCC cells was documented using a nude rat model[57]. Further, nanoparticles displaying HN-1 peptide effectively penetrated solid tumors derived from human oral squamous cell carcinoma SCC-25 cells in a murine xenograft model[62]. Through these
works, the pharmacological properties of HN-1 have been confirmed globally.

The unique properties of HN-1 have been exploited to develop novel anticancer therapeutics (Figure 4B). In 2009, Henri et al. [64] (Tapestry Pharmaceuticals, Boulder, United States) developed targeted chemotherapy comprised of HN-1 peptide and taxol. Taxol is an antimicrotubule drug that induces lethality by triggering ‘hyperploid progression mediated death’ in G1 DNA damage checkpoint defective human cancer cells due to mutant Rb or p53 gene [16, 24, 68]. The authors delineated a series of complex organic chemistry synthesis steps to conjugate HN-1 to taxol without affecting the latter’s antimicrotubule property. Using a murine xenograft model derived from human head and neck cancer FaDu cells, the authors demonstrated that the HN-1 peptide-to-taxol conjugate completely suppresses the growth of tumors. Further, it exhibited synergy with a second chemotherapeutic agent against breast, lung, uterine, or colon cancer cells. Of significance, the combined regimen increased growth inhibition from <15% (by a single agent) to ~80% against breast cancer cells. For drug resistance, the conjugate showed activity against multi-drug resistant human uterine sarcoma cells.

In 2007, Zheng (University of Texas health Science Center, San Antonio, United States) developed HN-5 (CYTSPNLHNGQKL), a derivative of HN-1 peptide containing one cysteine and one tyrosine residue at the N terminus [57]. Using HN-5 peptide radiolabeled with Cu-64 gamma-ray emitter, human HNSCC cell-derived tumor xenograft in a nude rat model was successfully imaged via positron emission tomography. HN-5 peptide exhibited specificity and affinity to HNSCC and exhibited a high diffusion capacity within a solid tumor. More significantly, by conjugating to HN-5, a significant reduction in the accumulation of unconjugated Cu-64 radioisotopes in the liver, heart, kidney, lung, and small intestine was observed. Subsequently, in 2013, Nordquist (University of Texas Health Science Center, San Antonio, United States) quantitatively documented selective accumulation of the radiolabeled HN-5 peptide in HNSCC-derived tumor xenografts. Of relevance, HN-4 peptide linked to the radioisotope Tc-99m has been presented at the 2007 American Association for Advancement of Science annual meeting.

In 2008, the HN-4 peptide was used to develop a human HNSCC-targeting liposome for targeted drug delivery. The components used to construct the liposomes included the lipids DPPC, DMPG, and PEG. The synthesis involved the preparation of lipid film, reconstitution in sucrose solution, and extrusion to limit particle size to 100 nm, which was presented at the 2008 Texas Science & Engineering Fair.

In 2010, Bao et al. [59] (Ohio State University Medical Center, Columbus, United States) developed HN1-PKC(epsilon), a capped bi-functional peptide comprised of HN-1 peptide and PKC(epsilon)-inhibitory peptide connected through a linker. The bifunctional inhibitory peptide was selectively internalized by human HNSCC cells and suppressed the growth of HNSCC xenograft in nude mice. The report also extended the targets of HN1 peptide to breast cancer. Of clinical significance, whereas cisplatin alone inhibited the growth of HNSCC cells by 49%, combining cisplatin with the above bi-functional peptide suppressed growth by 72%.

In 2011, Potala et al. [60] (Indian Institute of Technology Madras, Chennai, India) developed a novel fusion toxin comprised of HN-1 peptide and diphtheria toxin. The fusion toxin displayed a high degree of selectivity towards HNSCC and exhibited IC50 of 1-5 nM (nanomolar). They characterized ‘energy-dependent clathrin-mediated endocytosis’ as the HN-1 entry route and identified the intracellular punctate particles containing internalized HN-1 peptides as endosomes. The authors also found that the internalized fusion toxin utilized the translocation domain (of diphtheria toxin) to gain entry into the cytosol from endosomes.

In 2011, Dudas et al. [55] (Medical University Innsbruck, Innsbruck, Austria) reported that the pharmacological properties of HN-1 peptide could be recapitated using distinct human HNSCC cells. Further, the authors reported a seminal finding that the binding of HN-1 peptide to human HNSCC cells occurred in attached but not suspended cells [55]. It suggested that the expression level of the cognate cell surface receptor for HN-1 is governed by the presence of an extracellular matrix to which it adheres, providing an important clue for the discovery of DDR1 as the putative receptor for HN-1 peptide (see above).

In 2012, for gene therapy, Un et al. [58] (Beckman Research Institute of City of Hope National Medical Center, Duarte, United States) developed a therapeutic conjugate composed of HN-1(Tyr) and a siRNA targeting human ribonucleotide reductase subunit M2. HN-1(Tyr) contains two tyrosine residues added N-terminally to the HN-1 peptide [58]. The siRNA(R) resistant to RNase degradation was designed by J. Rossi (City of Hope National Medical Center, Duarte, United States) [69] and was able to suppress endogenously expressed ribonucleotide reductase in vivo after delivering in a nanoparticle constructed by M. Davis (California Institute of Technology, Pasadena, United States) [70]. The clinical trial involving melanoma patients was conducted by Y. Yen (Beckman Research Institute of City of Hope National Medical Center, Duarte, United States), a former colleague of J. Doroshow (National Cancer Institute, Bethesda, United States). For RNA interference therapy, the HN-1(Tyr)-anti-hRRM2 siRNA(R) construct moderately suppressed the endogenously expressed ribonucleotide reductase M2 subunit in breast cancer cells.

In 2017, Wang et al. [62] (Tianjin Medical University, Tianjin, China) constructed a nanoparticle comprised of polyethylene glycol via self-assembly, which contained the chemotherapeutic doxorubicin. Doxorubicin’s primary anticancer activity is associated with its propensity to intercalate with double-stranded DNA and inhibit topoisomerase II, and it has been used to treat leukemia, breast, lung,
bladder, and other cancers. The nanoparticle was further modified to display HN-1 peptide at the exterior[62,71]. The spherical construct (~150 nanometers) exhibited HNSCC-specific uptake and cytotoxicity. In vivo, HN-1 peptide endowed greater HNSCC targeting capacity and tumor penetrating potential to the PEGylated nanoparticle. Whereas unconjugated doxorubicin remained at the periphery, HN-1 Linked nanoparticle readily infiltrated to deeper regions of the tumor. The clinical use of doxorubicin is hampered by side effects—especially, cardiac damage. Intriguingly, a significantly lower amount (~1/15 fold) of doxorubicin accumulated in the heart and other organs (ex. liver, kidney, spleen, lung) after administering the construct in a murine xenograft model.

In 2017, Rossfeld et al[66] (Arthur G. James Comprehensive Cancer Center and Ohio State University, Columbus, United States) developed a conjugate comprised of the near-infrared dye IRdye800 and HN-17 (TLPNSNH KQGL), a derivative of HN-1 peptide, for intraoperative fluorescence imaging of tumors for optical surgical navigation. HN-17 (also called Compound-17) differs significantly from HN-1 at the primary structural level as it consists of a differentially permuted version of the HN-1 sequence. Though the sequence of HN-17 is comprised of identical amino acids (or their representation) as HN-1, it may not necessarily utilize the same entry mechanism as HN-1 (as indicated by its considerably faster rate of uptake). Further, whether HN-17 targets the same types of cancer as HN-1 is not known. Nevertheless, the study demonstrated that HN-1 peptide or its derivatives target medullary thyroid cancer. Subsequently, in 2019, Ding et al[65] (Ohio State University, Columbus, United States) demonstrated that IRdye800 conjugated HN-1 or HN-17 peptide could be used for fluorescence image guided resection of HNSCC during surgery using an animal model harboring an HNSCC-derived tumor xenograft.

In 2021, Li et al[63] (Shanxi Medical University School and Hospital of Stomatology, Taiyuan, China) developed a pH-sensitive (for drug release) delivery vector comprised of HN-1 peptide and nanoscale graphene oxide. After introducing polyethylene glycol to stabilize nanoscale graphene oxide, the construct was further modified to display HN-1 peptide to provide specificity for oral squamous cell cancer and achieve greater penetration into solid tumors. Doxorubicin was then loaded through the formation of hydrogen bond and pie-bond, which is weakened in an acidic milieu to allow drug release. Nearly 70% release of loaded drugs occurred at pH 5.6 compared to a significantly lower percentage at pH 7.4. As the tumor tissue exhibits an acidic environment, lower toxicity of the doxorubicin-containing nanoparticle to normal tissues (displaying higher pH) is expected.

**CONCLUSION**

In closing, we would like to reiterate that the accumulation of systemically administered cytotoxic anticancer drugs at various normal tissues following the intravenous injection can be debilitating for many cancer patients. To a large extent, the failure to guide drugs to tumors (resulting in < 0.5% of drugs reaching tumors) represents one of the major causes of side effects. Given the number of obstacles that the microenvironment of solid tumors poses (ex. stroma, basement membrane, interstitial pressure), overcoming these hindrances remains a major challenge in drug delivery. To reduce side effects, tumor-homing vectors are increasingly sought for targeted delivery. The use of previously developed vectors has been limited by inefficient penetration into solid tumors. Through the isolation of tumor specifically internalizing peptides such as HN-1, we have begun to chip away at the formidable problem of eliminating side effects associated with current drugs—hence, providing a molecular biological solution to the drug delivery problem. Following its discovery, multiple laboratories located globally have developed HN-1 conjugated therapeutics to mitigate side effects[61]. The international effort has been extended to developing imaging agents for tumor diagnosis as well as surgical navigation. Taken together, these works confirm the tumor specificity of the HN-1 peptide and underscore the expanding repertoire of its therapeutic application. Finally, the deciphering of clues that pointed to DDR1 tyrosine kinase as the putative receptor of HN1 may prove to be critical in moving toward clinical application. Further studies are planned to assess HN-1 peptide’s interaction with DDR1 and the therapeutic potential of treating metastatic cancer.

**ARTICLE HIGHLIGHTS**

**Research background**

The genetic basis of human cancers was elucidated via the identification of the prototypic human tumor suppressor retinoblastoma (Rb) gene by F. Hong (previously worked on phosphate transferase system governing diauxie at the Johns Hopkins University, whose alternate interpretation inspired operon concept) at the University of California at San Diego. His determination of the Rb gene sequence helped to uncover the central role of Rb in regulating the cell cycle as a component of DNA damage checkpoint at the G1 or S phase, which is regulated by cyclin-dependent kinase (Cdk) resulting in FDA-approved Cdk4/6 inhibitors for treating advanced-stage breast cancer. His discovery of Rb’s intrinsic properties to
interact with DNA as well as to form oligomers like the breast cancer type 1 susceptibility protein C-terminus (BRCT) laid the foundation for understanding Rb’s function in regulating DNA replication, transcription (ex. E2F), epigenetics (histone modification), heterochromatin, and condensation. These works culminated in his discovery of the tumor-specific lytic path ‘hyperploid progression mediated death’ targeting Rb or p53 mutant cancers.

Research motivation
Metastatic cancer diagnosed in late-stage remains a formidable challenge, often resulting in mortality. Combinatorial regimens consisting of multiple chemotherapeutic agents administered to treat metastatic cancer incur an unacceptably high level of morbidity.

Research objectives
There is a great unmet need to direct or guide the intravenously injected drugs to tumors as less than 0.5% reach tumors currently, contributing to severe side effects.

Research methods
Harnessing the power of molecular biology, random peptide displaying M13 bacteriophage-based library was screened by F. Hong, who previously utilized the recombinant phages to determine the genomic sequence of avian infectious bronchitis virus’ spike protein for vaccine development at the Salk Institute, which predated the emergence of COVID-19 coronavirus. The screening was conducted at the University of Texas M. D. Anderson Cancer Center using live surgically derived human head and neck squamous cell carcinoma cells. After screening \(2.5 \times 10^{12}\) random peptides, a single peptide TSLNIHNGQKL (HN-1) was isolated, which is tumor-specific, translocates across the cell membrane, and capable of penetrating solid tumors for targeted drug delivery.

Research results
Through global participation, the above properties of the HN-1 peptide have been confirmed. The international endeavor also led to the development of numerous HN-1 peptide conjugated agents for therapy (taxol, doxorubicin, protein kinase C inhibiting peptide, ribonucleotide reductase inhibiting siRNA, diphtheria toxin, polyethylene glycol linked to doxorubicin, graphene oxide nanoparticle-containing doxorubicin) as well as imaging (gamma-ray emitting isotopes for radiotherapy, near-infrared fluorescent dyes for surgical navigation) of cancer. More significantly, we now know that HN-1 peptide also targets breast and thyroid (potentially cervical, lung, uterine, colon) cancers.

Research conclusions
While analyzing its amino acid content, an important clue was obtained that pointed to discoidin domain receptor 1 (DDR1) as the HN-1 peptide’s cognate receptor. The finding is in alignment with previously accrued experimental data globally concerning the uptake route of HN-1. The identification of Rb-regulated DDR1 as the putative receptor for HN-1 opens unexpected opportunities to block cancer progression via targeting the very protein mediating metastasis.

Research perspectives
Through abrogating metastasis, it may preempt the recurrence of refractory metastatic cancers, which inevitably arise due to the acquiring of drug resistance.

ACKNOWLEDGEMENTS
We are grateful to Tri Ngo (Bio-Synthesis, Lewisville, United States) and D. Root (University of North Texas, Denton, United States) for molecular modeling. Also acknowledged are R. Dulbecco (Nobel prize 1975, oncogenic virus) of Salk Institute (La Jolla, United States), and the staff at Geary’s (Beverly Hills, United States). The discovery of HN-1 peptide by F. Hong was preceded by his prior works on gene transfer using lambda bacteriophage with S. Roseman (Johns Hopkins University, Baltimore, United States) in 1981-82, M13 single-stranded bacteriophage with J. Rose (a former colleague of D. Baltimore, Nobel prize 1975, reverse transcriptase) at the Salk Institute (La Jolla, United States) in 1984-1985, retroviral gene therapy vector from D. Miller (a former colleague of I. Verma, Salk Institute) at the Fred Hutchinson Cancer Research Center (Seattle, United States) in 1993, baculovirus gene expression system with D. Schubert (a former colleague of F. Jacob, Nobel prize 1966, operon) at the Salk Institute (La Jolla, United States) in 1993-1995, and adenovirus gene delivery vector with P. Nisen (a former colleague of S. Cohen, Nobel prize 1986, epidermal growth factor) at the University of Texas Southwestern Medical Center (Dallas, United States) in 1996-1997. F. Hong (consultant to the Beckman Research Institute of City of Hope National Medical Center) is listed as an inventor in United States patent 6,919,425 for HN-1 peptide filed by Fulbright & Jaworski (United States Special Prosecutor during the Watergate Scandal, Richard Nixon presidency) law firm (Houston, United States).
FOOTNOTES

Author contributions: Hong FU has worked on cancer genetics and molecular pharmacology; Castro M participated in therapeutics research; Linse K performed molecular modeling to predict the structure of peptides; Hong FU, Castro M, and Linse K meet the criteria for authorship established by the International Committee of Medical Journal Editors and verify the validity of the results reported; Hong FU wrote the manuscript; all authors approved the final version of the article.

Conflict-of-interest statement: Dr. Hong has received royalties from University of Texas M. D. Anderson Cancer Center patent covering materials related to HN-1 peptide. All other authors have nothing to disclose.

Data sharing statement: No additional data available.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United States

ORCID number: Frank-Un Hong 0000-0002-6814-4671; Miguel Castro 0000-0002-5499-5061; Klaus Linse 0000-0003-0408-9391.

S-Editor: Gong ZM
L-Editor: A
P-Editor: Gong ZM

REFERENCES


32 Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. *Science* 1997; 278: 1073-1077 [PMID: 9353183 DOI: 10.1126/science.278.5340.1073]


41 Jin H, Ham IH, Oh HJ, Bae CA, Lee D, Kim YB, Son SY, Chwae YJ, Han SU, Brekken RA, Hur H. Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. *Mol Cancer Res* 2018; 16: 1590-1600 [PMID: 29866925 DOI: 10.1158/1538-7766.MCR-17-0710]


54 Un F. Finding the genetic solution for cancer in the mechanism of Taxol cytotoxicity. In: Meszaros A, Balogh G. Multiple

---

**Hong FU et al. DDR1 as putative HN-1 receptor**

---

**WJCO**

[https://www.wjgnet.com](https://www.wjgnet.com)


